Jialin Mao

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma
    Jialin Mao
    Department of Drug Disposition, Eli Lilly and Co Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:591-602. 2011
  2. doi Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions
    Jialin Mao
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:706-16. 2012
  3. doi Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole
    Bing Han
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Drug Metab Dispos 41:1329-38. 2013

Collaborators

Detail Information

Publications3

  1. doi Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma
    Jialin Mao
    Department of Drug Disposition, Eli Lilly and Co Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 39:591-602. 2011
    ..Thus, HHSHP produced accurate DDI predictions with a simple IC(50) determined at a single incubation time regardless of the inhibition mechanism; further if needed, the mechanism(s) of inhibition can be identified...
  2. doi Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions
    Jialin Mao
    Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Metab Dispos 40:706-16. 2012
    ..In conclusion, the HHSHP system proved to be a simple, accurate predictor of DDIs for three major P450s and superior to the protein-free approach...
  3. doi Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole
    Bing Han
    Department of Drug Disposition, Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Drug Metab Dispos 41:1329-38. 2013
    ..Model 2 is not recommended for inferring optimal study design and estimation of fraction metabolized by CYP3A...